Symptoms sometimes referred to as Breast Implant Illness

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) addresses Breast Implant Illness (BII), a term used to describe symptoms such as fatigue, brain fog, and joint pain associated with breast implants. While these symptoms were reported as early as the 1990s, a 1998 Independent Review Group report found no definitive scientific link between silicone gel implants and long-term systemic illness. Currently, the MHRA, alongside the Department of Health and Social Care, continues to monitor safety data from all implant types, including silicone and saline models. Main issues center on patient reports of varied health problems and autoimmune disorders, some of which reportedly improve upon implant removal. Despite the lack of a proven causal link, the MHRA emphasizes patient safety through its regulatory framework, supported by the Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG) and clinical stakeholders like the ABS, BAAPS, and BAPRAS. Required actions include mandates for surgeons to provide comprehensive pre-operative counseling regarding both known and unknown risks to ensure informed consent. Prospective patients must receive detailed information sheets. Furthermore, the MHRA strongly encourages healthcare professionals and patients to report any suspected adverse incidents through the Yellow Card scheme, providing specific details such as implant model and batch numbers. This evidence-based approach ensures that the regulatory body can update safety advice as new research emerges.